## Gland Pharma Limited (GLAND) Stock Analysis - December 20, 2024

This report analyzes Gland Pharma Limited's (GLAND) stock performance and financial health based on the provided data to determine whether it's a buy, sell, or hold.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | GLAND                     |
| Company Name     | Gland Pharma Limited       |
| Industry         | Pharmaceuticals           |
| Listing Date     | November 20, 2020        |
| ISIN             | INE068V01023              |


**1.2 Market Data:**

| Metric                | Value      |
|-----------------------|-------------|
| Last Price            | 1,770.00    |
| Change                | -7.60       |
| % Change              | -0.43%      |
| Previous Close        | 1,777.60    |
| Open                  | 1,790.00    |
| Close                 | 1,772.30    |
| VWAP                  | 1,782.16    |
| Week High             | 2,220.95    |
| Week Low              | 1,585.70    |
| Sector PE             | 42.35       |
| Symbol PE             | 42.35       |
| Total Traded Volume   | 101,436     |
| Delivery Quantity     | 58,752      |
| Delivery %            | 57.92%      |
| CM Daily Volatility   | 2.26%       |
| CM Annual Volatility  | 43.18%      |


**1.3 Pre-Open Market Data:**

The pre-open market showed a slight downward trend, with the final pre-open price (1790) higher than the last price (1770).  However, the volume was low (163).

**1.4 Corporate Actions:**

| Ex-Date      | Purpose                                      |
|--------------|----------------------------------------------|
| August 16, 2024 | Annual General Meeting/Dividend - Rs 20 Per Share |
| August 6, 2021  | Annual General Meeting                       |


**1.5 Recent Announcements:** (Partial list, showing only subjects)

* Analysts/Institutional Investor Meet/Con. Call Updates
* Press Release
* Updates
* Shareholders meeting
* Change in Directors/ Key Managerial Personnel
* Change in Management


**1.6 Financial Results (Last Five Quarters):**  (All figures in INR Lakhs)

| Quarter Ending     | Income      | Expenditure | Profit After Tax | Diluted EPS |
|---------------------|-------------|-------------|-----------------|-------------|
| September 30, 2024 | 11,207.93   | 7,409.77    | 2,817.10        | 17.10       |
| June 30, 2024      | 10,605.14   | 7,601.99    | 2,229.21        | 13.53       |
| March 31, 2024     | 12,217.85   | 7,890.97    | 3,214.11        | 19.51       |
| December 31, 2023  | 11,412.51   | 7,694.96    | 2,768.05        | 16.81       |
| September 30, 2023 | 10,517.81   | 7,047.18    | 2,575.27        | 15.64       |


**1.7 Shareholding Patterns:**

| Date          | Promoter & Promoter Group | Public |
|---------------|--------------------------|--------|
| September 30, 2023 | 57.86%                     | 42.14% |
| December 31, 2023 | 57.86%                     | 42.14% |
| March 31, 2024    | 57.86%                     | 42.14% |
| June 30, 2024     | 51.83%                     | 48.17% |
| September 30, 2024| 51.83%                     | 48.17% |

A significant decrease in promoter holding is observed between March 2024 and June 2024.


**1.8 Key Directors and Contact Information:**

(A partial list is provided due to data limitations.  Full details are available in the original data.)

* **Chairperson & Executive Director-CEO:** Srinivas Sadu
* **Registrar:** Link Intime India Private Ltd. (Contact details available in original data)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

The current price (1,770) is below the previous close (1,777.60), indicating a slight downward trend.  It's also below the week's high but above the week's low. The pre-open activity showed a higher price than the closing price, suggesting some buying interest.

**2.2 Financial Performance:**

Revenue shows some fluctuation but generally remains above 100 Crores. Profit after tax and diluted EPS also show some fluctuation, but generally remain positive.  The decrease in promoter holdings warrants further investigation.

**2.3 Shareholding Analysis:**

Promoter holdings decreased significantly from 57.86% to 51.83% between March and June 2024. This needs further investigation to understand the reasons behind this reduction.

**2.4 Corporate Action Summary:**

A dividend of Rs 20 per share was declared.

**2.5 Volatility and Risk:**

Daily volatility is relatively low (2.26%), while annual volatility is moderate (43.18%).  The significant drop in promoter holdings increases the risk profile.

**3. Final Verdict:**

**Hold.**

**Reasoning:**

While the company shows generally positive financial performance with consistent profitability and a recent dividend payout, the significant drop in promoter holdings raises concerns.  Further investigation is needed to understand the reasons behind this decrease.  Until more information is available to clarify this significant change in shareholding, a "Hold" recommendation is prudent.  The relatively low daily volatility suggests a less risky investment, but the moderate annual volatility and the drop in promoter holdings introduce uncertainty.

**Conclusion:**

Gland Pharma Limited presents a mixed picture.  Positive financial results are offset by a concerning decrease in promoter holdings.  A "Hold" recommendation is advised until the reasons for the decreased promoter holding are clarified.  Investors should monitor the situation closely and seek further information before making any investment decisions.
